Clinical Practice Guideline: Allergic Rhinitis Executive Summary

Transcription

1 Clinical Practice Guideline: Allergic Rhinitis Executive Summary By: Nada Alouda, intern Article provided by: Dr. Amal Bin Hazza Otolaryngology/H&NS Dep. 2018

2

3 Quality improvement opportunity Guideline: 14 action statements Evidence quality Harm-benefit balance

4 Statement 1. Patient History And Physical Examination Recommendation based on observational studies. To promote a consistent and systematic approach to initial evaluation of the patient with allergic rhinitis. Grade C, based on observational studies. Benefits: Avoid unnecessary treatment or testing, have appropriately timed referral, institute a specific therapy, and improve accurate diagnosis. Harms: Inappropriate treatment, potential misdiagnosis from using Hx & PE alone.

5 Statement 2. Allergy Testing Recommendation based on RCT and systematic reviews. Improve accurate diagnosis and avoid unnecessary testing. Grade B, based on randomized controlled trials and systematic reviews. Benefits: Confirming diagnosis, directing pharmacologic therapy, directing immunotherapy, avoidance of ineffective therapy, reducing cost of unnecessary testing. Harms: Cost of testing, adverse events from testing, misinterpretation of results, inaccurate test results.

6 Statement 3. Imaging Recommendation against based on observational studies. Reduction of potential harm from unnecessary radiation exposure. Grade C, based on observational studies. Benefits: Avoiding unnecessary radiation exposure, reduction of cost. Harms: Inaccurate or missed diagnosis of pathology with similar presenting symptoms.

7 Statement 4. Environmental Factors Option based on RCT with minor limitations and observational studies. Reduce expenditures on environmental measures that do not improve symptoms. Grade B, based on randomized controlled trials with minor limitations and observational studies. Benefits: Decreased allergen levels and possible reduction in symptoms. Harms: Cost of environmental controls, emotional effect (ie, recommending animal avoidance in pet lovers), cost of ineffective recommendation.

8 Statement 5. Chronic Conditions And Comorbidities Recommendation based on randomized trials with some heterogeneity. Identification of significant comorbid conditions or complications. Potential for treatment optimization. Grade B, based on randomized trials with some heterogeneity. Benefits: Increased awareness of these conditions, identification of treatable conditions, and knowledge of these conditions may alter recommendations for allergic rhinitis treatment as comorbid conditions can alter response to treatment. Harms: Potential erroneous diagnosis of comorbid conditions.

9 Statement 6. Topical Steroids Strong Recommendation based on RCT with minor limitations. Optimizing the use of proven effective therapy. Grade A, based on randomized controlled trials with minor limitations. Benefits: Improved symptom control, improved QOL, better sleep, potential cost saving with monotherapy, targeted local effect. Harms: Topical side effects, epistaxis, potential growth concerns in children, septal perforation, and the cost of medication.

10 Statement 7. Oral Antihistamines (2 nd G) Strong Recommendation based on RCT with minor limitations. Avoidance of sedating antihistamine use and promotion of use of effective symptom-directed therapy. Grade A, based on randomized controlled trials with minor limitations. Benefits: Rapid onset of action, oral administration, relief of symptoms, over-the-counter availability, potentially cost saving, relief of eye symptoms. Harms: Systemic side effects (sedation), dry eyes, urinary retention.

11 Statement 8. Intranasal Antihistamines Option based on RCT with minor limitations and observational studies. Improve awareness of this class of medications as another effective treatment for allergic rhinitis that may be an alternative to other medication classes. Grade A, based on randomized controlled trials with minor limitations and observational studies. Benefits: Rapid onset, increased effectiveness over oral antihistamines for nasal congestion. Harms: Increased cost relative to oral antihistamines, poor taste, sedation, more frequent dosing, epistaxis, local side effects.

12 Statement 9. Oral Leukotriene Receptor Antagonists Recommendation against based on RCT and systematic reviews. Reduced use of a less effective agent for initial therapy. Grade A, based on randomized controlled trials and systematic reviews. Benefits: Avoid ineffective or less effective therapy, cost saving. Harms: There may be a subset of patients who would benefit from this medication (ie, patient with both AR and asthma).

13 Statement 10. Combination Therapy Option based on RCT with minor limitations and observational studies. Improve symptom control. Grade A, based on randomized controlled trials with limitations, observational studies. Benefits: improved effectiveness and symptom control of combined therapy. Harms: Increased cost, overuse of medication, use of ineffective combinations, multiple medication side effects, drug interactions.

14 Statement 11. Immunotherapy Recommendation based on RCT and systematic reviews. Increased appropriate use of immunotherapy and reduce variation in care, increased awareness of immunotherapy. Grade A, based on randomized controlled trials and systematic reviews. Benefits: Altered natural history, improved symptom control, decreased need for medical therapy, long- term cost effectiveness, may improve or prevent asthma or other comorbidities, and may prevent new sensitizations. Harms: Local reactions, and systemic reactions including anaphylaxis, increased initial cost, frequency of treatment, pain of injection, delayed onset of symptom control (months).

15 Statement 12. Inferior Turbinate Reduction Option based on observational studies. Improved nasal breathing and QOL. Grade C, based on observational studies. Benefits: Improved symptoms, improved QOL, improved medication delivery, reduced medication use, better sleep. Harms: Unnecessary surgery, cost of surgery, risks of surgery, atrophic rhinitis.

16 Statement 13. Acupuncture Option based on RCT with limitations, observational studies Increased awareness of acupuncture as a treatment option for AR. Grade B, based on RCT with limitations, observational studies with consistent effects. Benefits: Effective alternative to medical therapies, may more closely align with patient values, improved quality of life, avoidance of medication use and potential side effects. Harms: Need for multiple needle sticks, cost of treatment, rare infections.

17 Statement 14. Herbal Therapy No recommendation based on limited knowledge of herbal medicines, concern about the quality of standardization, and safety. Not applicable. Uncertain. Benefits: Improved awareness of alternative treatments, improved education of side effects of herbal therapy. Harms: Not applicable.

18 Conclusion: The recommendations outlined in the guideline are not intended to be an all- inclusive guide for patient management, nor are intended to limit treatment provided to individual patients or replace clinical judgment. Its goal is to create a multidisciplinary guideline with a specific set of focused recommendations based on an established and transparent process that considers levels of evidence, harm-benefit balance. The responsible physician, in light of all circumstances presented by the individual patient, must determine the appropriate treatment.

19 Reference: - Article: Clinical Practice Guideline: Allergic Rhinitis Executive Summary. Thank you